Business
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:\n\n\nCompany management presented 2 Phase IIb clinical trial posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which was held from April 8-13, 2022 in New Orleans, Louisiana\n\n\nBoth abstracts can be viewed below, and both posters, CT166 and CT161, can be accessed or downloaded from the Clinical Trials tab of the Company website at: https://greenwichlifesciences.com/clinical-trials/\n\n\nAbstract and poster CT166 demonstrated that GLSI-100 safely elicited a potent immune response, as evidenced by injection site reactions that correlate to and may serve as a complement to other immune response tests. The trastuzumab treated HER2 positive breast cancer patients appeared to be in a reduced immune state that was reversed with the addition of GP2, resulting in a significantly increased immune response that may protect against future metastatic breast cancer recurrence.\n\n\nAbstract and poster CT161 demonstrated that GP2 may be a natural antigen that is present before any GP2 treatment, suggesting that GP2 is a relevant target for T cell immunotherapy. In addition, a GP2 immune response prior to any GP2 treatment may help in predicting the probability and timing of breast cancer recurrence.\n\n\nAACR Abstract CT166:\n\nTitle: Injection site reactions correlate to delayed type hypersensitivity tests and suggest that GP2 reverses immune suppression of trastuzumab-treated HER2 positive patients in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) vs. GM-CSF after adjuvant trastuzumab in HER2 positive women with breast cancer\n\nSnehal S Patel, David B McWilliams, Mira S Patel, Jaye Thompson and F Joseph Daugherty.\n\nGreenwich LifeSciences, Stafford, TX\n\nBackground: Injection site reactions and Delayed Type Hypersensitivity (DTH) tests in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial of GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 have be...